Philips Launches IntraSight Plus, a Revolutionary Platform for Interventional Cardiology
Royal Philips announces the launch of IntraSight Plus, its integrated interventional imaging platform, now approved for sale in the United States and Europe. This solution combines diagnostic and therapeutic planning tools into a single system for percutaneous cardiac interventions.
Integration of Cutting-Edge Technologies
IntraSight Plus merges Philips' IntraSight and SyncVision technologies. The platform incorporates Class IA intravascular ultrasound imaging, physiological assessment (iFR/FFR), co-registration, and real-time visualization of medical devices. It enables interventional cardiologists to diagnose, virtually plan treatment, guide device placement, and verify outcomes on a single screen. This approach addresses the challenges posed by the fragmentation of current systems, where intravascular ultrasound imaging and physiological measurements are typically separate.
Seamless Integration into Existing Philips Ecosystem
IntraSight Plus integrates seamlessly with the existing Philips ecosystem, including the Azurion interventional platform and PACS systems, enhancing interoperability within Philips-equipped catheterization labs. The first clinical case was performed on March 19, 2026, at the Cellitinnen-Krankenhaus St. Vinzenz hospital in Cologne, Germany, by Prof. Dr. Jan-Malte Sinning. The platform has received CE marking in Europe and FDA 510(k) clearance in the United States. Commercial availability is subject to market launch conditions and applicable regulatory requirements.
